Increased brain tumor resection using fluorescence image guidance in a preclinical model

Background and Objectives Fluorescence image‐guided brain tumor resection is thought to assist neurosurgeons by visualizing those tumor margins that merge imperceptibly into normal brain tissue and, hence, are difficult to identify. We compared resection completeness and residual tumor, determined b...

Full description

Saved in:
Bibliographic Details
Published inLasers in surgery and medicine Vol. 35; no. 3; pp. 181 - 190
Main Authors Bogaards, Arjen, Varma, Abhay, Collens, Sean P., Lin, Aihua, Giles, Anoja, Yang, Victor X.D., Bilbao, Juan M., Lilge, Lothar D., Muller, Paul J., Wilson, Brian C.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2004
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and Objectives Fluorescence image‐guided brain tumor resection is thought to assist neurosurgeons by visualizing those tumor margins that merge imperceptibly into normal brain tissue and, hence, are difficult to identify. We compared resection completeness and residual tumor, determined by histopathology, after white light resection (WLR) using an operating microscope versus additional fluorescence guided resection (FGR). Study Design/Materials and Methods We employed an intracranial VX2 tumor in a preclinical rabbit model and a fluorescence imaging/spectroscopy system, exciting and detecting the fluorescence of protoporphyrin IX (PpIX) induced endogenously by administering 5‐aminolevulinic acid (ALA) at 4 hours before surgery. Results Using FGR in addition to WLR significantly increased resection completeness by a factor 1.4 from 68±38 to 98±3.5%, and decreased the amount of residual tumor post‐resection by a factor 16 from 32±38 to 2.0±3.5% of the initial tumor volume. Conclusions Additional FGR increased completeness of resection and enabled more consistent resections between cases. Lasers Surg. Med. 35:181–190, 2004. © 2004 Wiley‐Liss, Inc.
Bibliography:NIH - No. CA 43892
ArticleID:LSM20088
ark:/67375/WNG-BWF2GPJL-K
istex:012583F19EB7C5961439CBD610CA59074445BA0D
DUSA Pharmaceuticals NY
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0196-8092
1096-9101
DOI:10.1002/lsm.20088